Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. clinical trials

A subsidiary of Sino Biopharmaceutical Limited

The registry lists 2 studies whose lead sponsor is Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 15, 2026.

Status

Completed: 2

Phase

Phase 2: 1
Phase 1: 1

Where

Australia: 1
China: 1

Registry sponsor names on this page

Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.2 studies

Something wrong with this grouping? Tell us on the Sino Biopharmaceutical Limited page.

Studies

Recruiting first, then most recently updated. Showing 2 of 2. All Sino Biopharmaceutical Limited studies →

Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101CompletedNCT06545162Phase 1
Sponsor listed in the registry: Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes MellitusCompletedNCT06532578Phase 2
Sponsor listed in the registry: Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.